UK Markets closed

Oil prices rise as U.S. crude stock draw supports but demand hopes dim

Laura Sanicola
·2-min read
FILE PHOTO: The sun sets behind the chimneys of the Total Grandpuits oil refinery southeast of Paris

By Laura Sanicola

LONDON (Reuters) -Oil prices settled higher on Wednesday, supported by a draw in U.S. crude inventories and Britain's approval of a second coronavirus vaccine but pressured by swelling year-over-year supply.

Brent crude futures settled up 25 cents to $51.34 a barrel, off the session high of $51.56 and well lower than the $66 price that started the year.

U.S. West Texas Intermediate (WTI) crude settled up 40 cents to trade at $48.40, substantially down from about $62 at the start of 2020.

Both contracts slipped early the session as a bigger fiscal aid package in the United States looked increasingly unlikely, dampening hopes for a swifter recovery of oil demand that has been hammered by the COVID-19 pandemic.

Prices rallied after an Energy Information Administration report showed crude inventories fell by 6.1 million barrels in the latest week to 493.5 million barrels. [EIA/S]

But traders noted that U.S. crude inventories still were ending the year more than 10% higher than the last week of 2019.

"We couldn't even pull down storage levels with a 6.1 million inventory draw which is sad but a reality, and it took the wind out of the sails for a big rally" said Bob Yawger, director of energy futures at Mizuho.

On the supply front, U.S. energy firms this week added 3 oil and natural gas rigs to the best quarter for boosting the rig count since the second quarter of 2017, according to data from Baker Hughes.

A Jan. 4 meeting of the Organization of the Petroleum Exporting Countries (OPEC) and allies, including Russia, a group known as OPEC+, is set to boost output by 500,000 barrels per day (bpd) in January.

Oil prices found some support on Wednesday from the U.S. dollar hitting its lowest against a basket of currencies since 2018, making oil cheaper for holders of other currencies.

Raising hopes of a faster normalization of travel and work, Britain on Wednesday became the first country to approve a coronavirus vaccine developed by the University of Oxford and AstraZeneca.

But vaccine rollout in the U.S. has rolled out slower than previously expected. Some 2 million people have been vaccinated, President-elect Joe Biden said on Tuesday, well short of the 20 million President Donald Trump had promised by the end of the year.

(Additional reporting Shadia Nasralla and Naveen ThukralEditing by David Goodman, David Gregorio, Aurora Ellis and Chizu Nomiyama)